查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602398

急性骨髓性白血病药物市场：依疾病类型、治疗类型、通路划分 - 全球预测 2025-2030

Acute Myeloid Leukemia Therapeutics Market (AML) by Disease Type (Myeloblastic, Myelomonocytic, Promyelocytic), Treatment Type (Chemotherapy, Targeted Therapy), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年急性骨髓性白血病治疗市值为9,2182万美元，预计2024年将达到10,2156万美元，复合年增长率为11.94%，2030年将达到20,304.9亿美元，预计将达到1000万美元。

急性骨髓性白血病(AML) 治疗范围包括 A​​ML 的诊断、治疗和持续管理，AML 是一种影响血液和骨髓的癌症，其特征是异常白血球快速增殖。随着人口老化，AML发生率不断上升，需要标靶治疗、化疗、骨髓移植等先进治疗方法，因此需要有效的AML治疗药物。这些疗法的应用包括缓解诱导/强化、维持治疗以及復发/难治性 AML 的治疗。最终使用范围主要限于专业知识集中的医院、癌症诊所和研究机构。

主要市场统计
基准年[2023] 9.2182亿美元
预测年份 [2024] 1,021,560,000 美元
预测年份 [2030] 2,030,490,000 美元
复合年增长率（%） 11.94%

AML治疗市场的开拓很大程度上是由基因组学技术进步所推动的，基因组学技术的进步使得个人化医疗和标靶治疗的发展成为可能。製药公司、学术机构和研究机构之间的联盟与合作正在进一步促进创新和可及性。然而，高治疗成本、副作用和已开发药物的商业化有限等限制阻碍了广泛采用，临床试验和监管核准流程的复杂性也是如此。新的商机在于加强药物输送系统、改进患者分层方法以及探索新的遗传标记以提高治疗效果并降低毒性。抓住这些机会的建议包括投资于研发、透过策略联盟共用资源和专业知识，以及专注于针对个别病患状况的精准医疗方法。

此外，他们还面临新药核准率因严格监管而缓慢、研发成本高且无法保证成功等挑战。创新领域包括开发生物相似药以降低成本、利用人体免疫反应的新型免疫疗法以及用于即时病患监测以动态调整治疗方法的数位工具。 AML治疗市场的特点是技术创新迅速，由于资本要求高和监管障碍而存在巨大的进入壁垒，但对于善于透过策略创新和伙伴关係关係克服这些挑战的公司来说，它具有无价的潜力。

市场动态：揭示快速发展的急性骨髓性白血病药物市场的关键市场洞察

供需的动态交互作用正在改变急性骨髓性白血病药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球急性骨髓性白血病患者的盛行率
    • 由于癌症治疗需求的不断增长，癌症意识计划的增加
    • 政府积极支持急性骨髓性白血病治疗
  • 市场限制因素
    • 急性骨髓性白血病药物高成本
  • 市场机会
    • 急性骨髓性白血病新疗法的开发
    • 急性骨髓性白血病药物核准率提高
  • 市场挑战
    • 与骨髓性白血病治疗相关的副作用

波特五力：驾驭急性骨髓性白血病药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对急性骨髓性白血病药物市场的影响

外部宏观环境因素在塑造急性骨髓性白血病药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解急性骨髓性白血病治疗药物市场的竞争状况

对急性骨髓性白血病药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵急性骨髓性白血病治疗市场供应商的绩效评估

FPNV定位矩阵是评估急性骨髓性白血病药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为急性骨髓性白血病药物市场的成功指明道路

对于希望加强在全球市场的影响力的公司来说，对急性骨髓性白血病药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 急性骨髓性白血病的全球盛行率
      • 随着癌症治疗需求的增加，癌症意识计画也随之增加
      • 政府支持急性骨髓性白血病治疗的有利倡议
    • 抑制因素
      • 急性骨髓性白血病治疗费用高
    • 机会
      • 急性骨髓性白血病新治疗方法的开发
      • 急性骨髓性白血病治疗药物核准率提高
    • 任务
      • 与骨髓性白血病治疗相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章急性骨髓性白血病治疗药物市场：依疾病类型

  • 成髓细胞
  • 骨髓单核细胞
  • 早幼粒细胞

第七章依治疗类型分類的急性骨髓性白血病治疗药物市场

  • 化疗
  • 标靶治疗

第八章急性骨髓性白血病治疗药物市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第九章北美和南美急性骨髓性白血病治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太地区急性骨髓性白血病药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲急性骨髓性白血病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc. by Otsuka Group
  • Celgene Corporation
  • CTI BioPharma Corp.
  • Cyclacel Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Janssen Global Services, LLC
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Merus NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol Myers Squibb Company
Product Code: MRR-02026C4C8B97

The Acute Myeloid Leukemia Therapeutics Market was valued at USD 921.82 million in 2023, expected to reach USD 1,021.56 million in 2024, and is projected to grow at a CAGR of 11.94%, to USD 2,030.49 million by 2030.

The scope of acute myeloid leukemia (AML) therapeutics involves the diagnosis, treatment, and ongoing management of AML, a form of cancer affecting the blood and bone marrow characterized by rapid growth of abnormal white blood cells. The necessity for effective AML therapeutics is driven by the increasing incidence of the disease, often related to aging populations, necessitating advanced treatment modalities like targeted therapies, chemotherapy, and bone marrow transplants. Applications of these therapeutics include induction and consolidation of remission, maintenance therapy, and addressing relapsed or refractory AML. End-use scope is largely restricted to hospitals, specialty cancer clinics, and research institutions, where specialized expertise is concentrated.

KEY MARKET STATISTICS
Base Year [2023] USD 921.82 million
Estimated Year [2024] USD 1,021.56 million
Forecast Year [2030] USD 2,030.49 million
CAGR (%) 11.94%

Market growth in AML therapeutics is primarily influenced by technological advancements in genomics, enabling personalized medicine and the development of targeted therapies. Partnerships and collaborations among pharmaceutical companies, academic institutions, and research bodies further fuel innovation and accessibility. However, constraints such as the high costs of treatment, side effects, and limited commercialization of developed drugs hinder widespread adoption, as does the complexity of clinical trials and regulatory approval processes. Emerging opportunities lie in enhancing drug delivery systems, improving patient stratification methods, and exploring novel genetic markers to increase therapeutic efficacy while reducing toxicity. Recommendations for capturing these opportunities include investing in R&D, forming strategic alliances to pool resources and expertise, and focusing on precision medicine approaches to cater to individual patient profiles.

Additionally, the market faces challenges like slow approval rates for new drugs because of stringent regulations, and significant R&D costs without guaranteed success. Areas ripe for innovation include the development of biosimilars to reduce costs, novel immunotherapies that harness the body's immune response, and digital tools for real-time patient monitoring to tailor treatment regimens dynamically. The AML therapeutics market is characterized by rapid technological change, substantial entry barriers due to high capital requirements and regulatory hurdles, but immense potential for companies adept at navigating these difficulties through strategic innovation and partnerships.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Myeloid Leukemia Therapeutics Market

The Acute Myeloid Leukemia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of acute myeloid leukemia cases worldwide
    • Increasing cancer awareness programs with growing need for cancer therapy
    • Favorable government initiatives to support the acute myeloid leukemia therapies
  • Market Restraints
    • High cost of acute myeloid leukemia therapies
  • Market Opportunities
    • Development of novel acute myeloid leukemia treatments
    • Rise in approval rate of acute myeloid leukemia therapeutics
  • Market Challenges
    • Adverse effects associated with the myeloid leukemia treatment

Porter's Five Forces: A Strategic Tool for Navigating the Acute Myeloid Leukemia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Myeloid Leukemia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Myeloid Leukemia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Myeloid Leukemia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Myeloid Leukemia Therapeutics Market

A detailed market share analysis in the Acute Myeloid Leukemia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Myeloid Leukemia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Myeloid Leukemia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Myeloid Leukemia Therapeutics Market

A strategic analysis of the Acute Myeloid Leukemia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Myeloid Leukemia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Actinium Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Amgen Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc. by Otsuka Group, Celgene Corporation, CTI BioPharma Corp., Cyclacel Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Janssen Global Services, LLC, Jazz Pharmaceuticals PLC, Johnson & Johnson Services, Inc., MEI Pharma, Inc., Merck & Co., Inc., Merus N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and The Bristol Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Acute Myeloid Leukemia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Myeloblastic, Myelomonocytic, and Promyelocytic.
  • Based on Treatment Type, market is studied across Chemotherapy and Targeted Therapy.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of acute myeloid leukemia cases worldwide
      • 5.1.1.2. Increasing cancer awareness programs with growing need for cancer therapy
      • 5.1.1.3. Favorable government initiatives to support the acute myeloid leukemia therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of acute myeloid leukemia therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel acute myeloid leukemia treatments
      • 5.1.3.2. Rise in approval rate of acute myeloid leukemia therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with the myeloid leukemia treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Myeloid Leukemia Therapeutics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Myeloblastic
  • 6.3. Myelomonocytic
  • 6.4. Promyelocytic

7. Acute Myeloid Leukemia Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Targeted Therapy

8. Acute Myeloid Leukemia Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Americas Acute Myeloid Leukemia Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Acute Myeloid Leukemia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Acute Myeloid Leukemia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Actinium Pharmaceuticals, Inc.
  • 3. Agios Pharmaceuticals, Inc.
  • 4. Amgen Inc.
  • 5. Astellas Pharma Inc.
  • 6. Astex Pharmaceuticals, Inc. by Otsuka Group
  • 7. Celgene Corporation
  • 8. CTI BioPharma Corp.
  • 9. Cyclacel Pharmaceuticals, Inc.
  • 10. Daiichi Sankyo Company, Limited
  • 11. Eisai Co., Ltd.
  • 12. F. Hoffmann-La Roche AG
  • 13. GlaxoSmithKline plc
  • 14. Janssen Global Services, LLC
  • 15. Jazz Pharmaceuticals PLC
  • 16. Johnson & Johnson Services, Inc.
  • 17. MEI Pharma, Inc.
  • 18. Merck & Co., Inc.
  • 19. Merus N.V.
  • 20. Novartis AG
  • 21. Pfizer Inc.
  • 22. Sanofi S.A.
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Teva Pharmaceutical Industries Ltd.
  • 26. The Bristol Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MYELOBLASTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MYELOMONOCYTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PROMYELOCYTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023